Yahoo Web Search

  1. Yahoo Finance Results

  2. Why Bristol-Myers Squibb Stock Crashed in April

    Motley Fool via Yahoo FinanceMay 09 15:20 PM

    Pfizer's (NYSE: PFE) management team noted halfway through the month that Bristol was not a top acquisition target due to the company's current valuation.

  3. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Index (PMI) data, output in the Healthcare sector is rising.

    52.77+0.08 (+0.15%)

    at Fri, May 25, 2018, 15:00PM EST - U.S. Markets closed

    After Hours 52.60 -0.17 (-0.32%)

    Delayed Quote

    • Open 52.81
    • High 53.00
    • Low 52.54
    • Prev. Close 52.69
    • 52 Wk. High 70.05
    • 52 Wk. Low 49.96
    • P/E 86.51
    • Mkt. Cap 86.28B
  4. Illumina Takes Over Edico Genome, Fortifies NGS Platform

    Zacks via Yahoo FinanceMay 16 12:52 PM

    Per the company, Edico Genome’s DRAGEN Bio-IT (DRAGEN) platform pairs well with Illumina’s sequencing portfolio and helps in delivering rapid and streamlined output for NGS customers.

  5. Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat

    Zacks via Yahoo FinanceMay 09 15:09 PM

    Clovis Oncology, Inc. CLVS incurred an adjusted loss of $1.54 per share in the first quarter of 2018, which was wider than the year-ago loss of $1.33 per share as well as the Zacks Consensus ...

  6. Is Agenus Inc. (AGEN) a Buy?

    Motley Fool via Yahoo FinanceMay 12 13:28 PM

    If they're eventually approved, Agenus will join a club that includes Bristol-Myers Squibb (NYSE: BMY) and Merck & Co. (NYSE: MRK).

  7. Following the news, the company’s shares went down 5.6%. Horizon Pharma’s stock has declined 5.4% year to date compared with the industry’s fall of 12.3%. The company reported ...

  8. J&J’s JNJ multiple myeloma drug Darzalex gained FDA approval for combination use in first-line setting while Roche RHHBY announced a couple of regulatory/pipeline updates on its PD-L1 inhibitor ...

  9. Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

    Zacks via Yahoo FinanceMay 09 18:12 PM

    Infinity Pharmaceuticals, Inc. INFI reported a loss of 18 cents per share in first-quarter 2018, in line with the Zacks Consensus Estimate.

  10. AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

    Zacks via Yahoo FinanceMay 09 14:57 PM

    The company is focused on launching the drugs in the European countries. The company is entitled to receive double-digit royalty payments from EUSA Pharma on net sales of the drug ...

  11. Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

    Zacks via Yahoo FinanceMay 11 13:59 PM

    Shares of the company fell 6.5% on May 10 on the wider-than-expected loss and discontinuation of development of three candidates including earlier announced glembatumumab vedotin.

  1. Ads
    related to BRISTOL-MYERS SQUIBB COMPANY